Conexeu Sciences recorded a $7,725,651 quarterly net loss, compared with a $1,298,570 loss a year earlier. The company says continuing operations depend on securing Debt or Equity Financing before generating positive cash flow, while substantial doubt remains about its ability to continue as a Going Concern within one year.

Key Highlights

  • Conexeu Sciences reported an accumulated Deficit of $16,270,277 as of July 31, 2026.
  • Cash and cash equivalents stood at $1,971,408, alongside $238,208 of restricted cash.
  • Warrant exercises generated gross proceeds of $1,753,998 at $2.30 per share on September 4, 2026.

Conexeu Sciences Inc. (NASDAQ: CNXU) recorded a net loss of $7,725,651 ($7.73M) for the three months ended July 31, 2026, compared with a $1,298,570 loss in the comparable period. The nine-month net loss reached $11,748,757, versus $2,046,684 previously.

Losses Accumulate Through July

Conexeu Sciences reported an accumulated deficit of $16,270,277 as of July 31, 2026, compared with $4,521,520 as of October 31, 2025. The company said it has incurred significant losses since inception and expects those losses to continue for the foreseeable future. The company has not generated Revenue to date. Its activities have focused on research and development, advancing its device candidate, Capital raises and preparations for operating as a publicly traded company.

Cash And Funding Need

Cash and cash equivalents totaled $1,971,408 ($1.97M) as of July 31, 2026, while restricted cash was $238,208. Cash and cash equivalents were $4,808,965 as of October 31, 2025, and restricted cash was $25,155. The company also reported an Investment at cost of $71,328 and a security deposit of $18,475. On September 4, 2026, four holders exercised warrants at $2.30 per share. The exercises produced gross proceeds of $1,753,998 ($1.75M), and Conexeu Sciences issued 762,608 shares of common stock. The proceeds are intended to support ongoing operations.

Controls Remain Under Remediation

The company said those controls had not operated long enough to permit a full evaluation of their effectiveness, leaving the material weakness under remediation as of July 31, 2026.

Funding Required For Continuity

Conexeu Sciences said continuation as a going concern depends on obtaining necessary debt or equity financing until it begins generating positive cash flow. The company said Debt Financing could impose restrictions on operations, while equity financing could substantially dilute common stockholders. Its common stock began trading on Nasdaq under CNXU on May 21, 2026. There were 28,206,698 shares of common stock outstanding as of September 10, 2026.